Background: MicroRNAs (miRs) are altered in breast tumors, influencing tumor development and progression. As miRs are remarkably stable in circulation, they also have enormous potential as non-invasive biomarkers for breast cancer. Indeed, circulating miRs have been detected in breast cancer patients, but interpretation of their relevance as minimally invasive biomarkers is limited by inconsistent results. Furthermore, the cellular source of circulating miRs and the molecular mechanisms regulating these potential miR biomarkers remain unclear. To address these issues, a highly relevant animal model for in vivo investigation of potential miR biomarkers was established. Aging mice with a Scurfy (sf) mutation of the X-linked tumor suppressor, Foxp3 (Foxp3sf/+), develop spontaneous breast cancer and tumor lung metastases. Analysis of circulating miRs in Foxp3sf/+ female mice revealed that plasma miR-200c/141 and miR-155 levels increase dramatically during tumor progression and lung metastasis, and these results were validated in a small population of breast cancer patients. Thus, these miRs appear as ideal candidates for novel biomarkers to detect the progression of human breast cancer and predict tumor response to therapies. Hypothesis and Goals: The central hypothesis is that circulating miR-200c/141 and miR-155 are useful biomarkers for early detection and prediction of tumor progression and therapeutic response. This hypothesis will be tested in three specific aims: 1) To validate potential miR biomarkers in a large patient population, 2) To determine the utility of the miR biomarkers in the early detection of tumor progression and prediction of therapeutic response, and 3) To elucidate the genesis and regulation of circulating miR biomarkers. Approach: First, the upregulation of the miR biomarkers identified in the Foxp3sf/+ mouse model will be validated in a large population of breast cancer patients using a TaqMan miR assay. The most optimal methods, materials, controls, and matched individuals will be used to ensure the statistical significance of this validation. Second, we will determine if the miR biomarkers are useful for the early detection of tumor progression, especially tumor metastasis. The utility of miR biomarkers in predicting response to treatments in breast cancer patients will be estimated by comparison with current biomarkers. Third, we will use FOXP3 Tet-off MCF7 cells to determine if miRs are released from breast cancer cells and regulated by FOXP3. The Foxp3sf/+ mouse model will be used to further investigate the cellular sources of circulating miR biomarkers. Innovation and Significance: This study will be the first to investigate 1) the utility of the miR biomarkers in predicting response o therapies, and 2) the mechanisms regulating circulating miR biomarkers during tumor progression in vivo. If confirmed, these miR biomarkers will provide non-invasive tools for improving outcomes and decreasing mortality in breast cancers with FOXP3 defects.

Public Health Relevance

Our proposed work will identify circulating microRNAs that may serve as biomarkers in breast cancer, which will provide new non-invasive approaches for monitoring tumor progression and predicting response to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA179282-02
Application #
8829797
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Lively, Tracy (LUGO)
Project Start
2014-05-01
Project End
2016-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
2
Fiscal Year
2015
Total Cost
$159,863
Indirect Cost
$51,113
Name
University of Alabama Birmingham
Department
Genetics
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650
Zhang, Guangxin; Zhang, Wei; Li, Bingjin et al. (2017) MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res 19:73
Wang, Chiung-Min; Wang, Raymond X; Liu, Runhua et al. (2017) Jun Dimerization Protein 2 Activates Mc2r Transcriptional Activity: Role of Phosphorylation and SUMOylation. Int J Mol Sci 18:
Meredith, Leslie J; Wang, Chiung-Min; Nascimento, Leticia et al. (2016) The Key Regulator for Language and Speech Development, FOXP2, is a Novel Substrate for SUMOylation. J Cell Biochem 117:426-38
Zhang, Wei; Yi, Bin; Wang, Chao et al. (2016) Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells. Clin Cancer Res 22:2545-54
Liu, Runhua; Liu, Cong; Chen, Dongquan et al. (2015) FOXP3 Controls an miR-146/NF-?B Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells. Cancer Res 75:1703-13
Chen, Dongquan; Li, Yufeng; Wang, Lizhong et al. (2015) SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma. Int J Breast Cancer 2015:539721

Showing the most recent 10 out of 12 publications